COMP <GO>
ZBH vs JNJ // REVENUE GROWTH (YOY)
Zimmer Biomet Holdings Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ZBH 5
— JNJ 9
▲ REVENUE GROWTH (YOY) LEADER: ZBH
LAST: $94.52 (-3.03%) • MKT CAP: $18.59B
revenue-growth
7.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZBH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZBH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.70% | 67.90% | +1.80 | ZBH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 25.50% | -20.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.3x | 18.5x | +0.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 7.92% | 2.97% | +4.95 | ZBH | /fcf-yield <GO> |
| Operating Margin | 13.30% | 34.70% | -21.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 8.60% | 28.50% | -19.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 7.20% | 6.00% | +1.20 | ZBH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.02% | 0.00% | +1.02 | ZBH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.42 | 5.59 | -3.17 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.20% | -0.20 | ZBH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 60.4 | -10.58 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.08 | -0.06 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.6x | 23.0x | +1.60 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.59B | $662.49B | -$643.90B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZBH REV | JNJ REV | ZBH GROSS % | JNJ GROSS % | ZBH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.23B | $94.19B | 69.7% | 67.9% | $1.47B | $19.70B |
| FY 2024 | $7.68B | $88.82B | 71.5% | 69.1% | $1.30B | $19.84B |
| FY 2023 | $7.39B | $85.16B | 44.0% | 44.0% | $1.25B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZBH // BETA 1.02
JNJ // BETA 1.08